An Analysis of the PROCLAIM 2007-2012 National Registry
Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry
Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry.
Clinical Pearls:
- IL-2 is an immunotherapy that can give complete responses that last years
- The database retrospectively looked back over a 5-year period
- The registry showed that IL-2 still gives an occasional, durable response
- The registry also showed that clinical factors such as normal LDH and patient performance status is important in determining who will be successful on IL-2
- Patients with stable disease or did not seem to respond to IL-2 initially had better overall survival than previously thought, according to the registry findings
<<<
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
